Spectrum Pharmaceuticals (NASDAQ:SPPI) CEO Joseph W. Turgeon sold 3,100 shares of Spectrum Pharmaceuticals stock in a transaction dated Thursday, March 22nd. The stock was sold at an average price of $18.17, for a total value of $56,327.00. Following the completion of the transaction, the chief executive officer now directly owns 332,884 shares in the company, valued at approximately $6,048,502.28. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of Spectrum Pharmaceuticals (SPPI) traded down $0.23 on Friday, reaching $17.28. The company had a trading volume of 880,541 shares, compared to its average volume of 1,180,455. The stock has a market cap of $1,886.87, a PE ratio of -16.30 and a beta of 1.59. Spectrum Pharmaceuticals has a 1 year low of $5.47 and a 1 year high of $23.50.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last released its earnings results on Tuesday, March 6th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.04). Spectrum Pharmaceuticals had a negative net margin of 70.66% and a negative return on equity of 30.68%. The business had revenue of $28.57 million for the quarter, compared to analysts’ expectations of $33.18 million. During the same period last year, the firm earned ($0.10) EPS. The company’s revenue was down 18.9% compared to the same quarter last year. analysts expect that Spectrum Pharmaceuticals will post -1.14 EPS for the current fiscal year.
SPPI has been the topic of a number of analyst reports. BidaskClub cut Spectrum Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 22nd. TheStreet cut Spectrum Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Friday, March 16th. Zacks Investment Research cut Spectrum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. HC Wainwright reissued a “buy” rating and issued a $29.00 price target on shares of Spectrum Pharmaceuticals in a research note on Monday, December 18th. Finally, B. Riley initiated coverage on Spectrum Pharmaceuticals in a research note on Monday, December 18th. They issued a “buy” rating and a $26.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $25.20.
ILLEGAL ACTIVITY WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3294058/joseph-w-turgeon-sells-3100-shares-of-spectrum-pharmaceuticals-sppi-stock.html.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients.
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.